Axsome Therapeutics Acquires Global Rights to AZD7325 for Epilepsy Treatment

Reuters

2025/11/06

Axsome <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Acquires Global Rights to AZD7325 for Epilepsy Treatment

Axsome Therapeutics has obtained exclusive global rights to AZD7325, a novel oral GABAA receptor α2,3 subtype-selective positive allosteric modulator, through the acquisition of 100% equity interest in Baergic Bio, Inc., a subsidiary of Avenue Therapeutics. The deal includes commercial, development, and manufacturing rights to AZD7325, which has shown anti-convulsant effects in preclinical seizure models and demonstrated a favorable safety and tolerability profile in clinical studies involving over 700 patients. Baergic Bio shareholders will receive a $0.3 million upfront payment, with potential development, regulatory, and sales-based milestone payments, as well as tiered royalties on global net sales. AstraZeneca, the original licensor, will receive a cash upfront payment in the single digit millions, additional milestone payments, and tiered royalties. Axsome plans to advance AZD7325 into Phase 2 trial-enabling activities for epilepsy in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570134-en) on November 06, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581062998"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581062998\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581062998?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581062998","market":"nz","top_or_hot":-1,"title":"Axsome Therapeutics Acquires Global Rights to AZD7325 for Epilepsy Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Axsome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Acquires Global Rights to AZD7325 for Epilepsy Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Axsome Therapeutics has obtained exclusive global rights to AZD7325, a novel oral GABAA receptor α2,3 subtype-selective positive allosteric modulator, through the acquisition of 100% equity interest in Baergic Bio, Inc., a subsidiary of Avenue Therapeutics. The deal includes commercial, development, and manufacturing rights to AZD7325, which has shown anti-convulsant effects in preclinical seizure models and demonstrated a favorable safety and tolerability profile in clinical studies involving over 700 patients. Baergic Bio shareholders will receive a $0.3 million upfront payment, with potential development, regulatory, and sales-based milestone payments, as well as tiered royalties on global net sales. AstraZeneca, the original licensor, will receive a cash upfront payment in the single digit millions, additional milestone payments, and tiered royalties. Axsome plans to advance AZD7325 into Phase 2 trial-enabling activities for epilepsy in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570134-en) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Axsome Therapeutics Acquires Global Rights to AZD7325 for Epilepsy Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAxsome Therapeutics Acquires Global Rights to AZD7325 for Epilepsy Treatment\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-06 20:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Axsome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Acquires Global Rights to AZD7325 for Epilepsy Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Axsome Therapeutics has obtained exclusive global rights to AZD7325, a novel oral GABAA receptor α2,3 subtype-selective positive allosteric modulator, through the acquisition of 100% equity interest in Baergic Bio, Inc., a subsidiary of Avenue Therapeutics. The deal includes commercial, development, and manufacturing rights to AZD7325, which has shown anti-convulsant effects in preclinical seizure models and demonstrated a favorable safety and tolerability profile in clinical studies involving over 700 patients. Baergic Bio shareholders will receive a $0.3 million upfront payment, with potential development, regulatory, and sales-based milestone payments, as well as tiered royalties on global net sales. AstraZeneca, the original licensor, will receive a cash upfront payment in the single digit millions, additional milestone payments, and tiered royalties. Axsome plans to advance AZD7325 into Phase 2 trial-enabling activities for epilepsy in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570134-en) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BFTCPJ56.SGD","symbol_name":"Janus Henderson Global Life Sciences A Acc SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL1MJDGy:1","article_id":"2581062998","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581062998","pubTimestamp":1762430536,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Axsome Therapeutics has obtained exclusive global rights to AZD7325, a novel oral GABAA receptor α2,3 subtype-selective positive allosteric modulator, through the acquisition of 100% equity interest in Baergic Bio, Inc., a subsidiary of Avenue Therapeutics. The deal includes commercial, development, and manufacturing rights to AZD7325, which has shown anti-convulsant effects in preclinical seizure models and demonstrated a favorable safety and tolerability profile in clinical studies involving over 700 patients. Baergic Bio shareholders will receive a $0.3 million upfront payment, with potential development, regulatory, and sales-based milestone payments, as well as tiered royalties on global net sales. AstraZeneca, the original licensor, will receive a cash upfront payment in the single digit millions, additional milestone payments, and tiered royalties. Axsome plans to advance AZD7325 into Phase 2 trial-enabling activities for epilepsy in 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK5011":"制药","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU1153584641.USD":"BGF EUROPEAN EQUITY INCOME \"A2\" (USDHDG) ACC","FBIO":"Fortress Biotech Inc.","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU1019632923.USD":"Blackrock European Equity Income A6 USD-H","LU0949170426.SGD":"Blackrock Global Multi-Asset Income A6 SGD-H","LU0889565080.SGD":"FTIF - Templeton European Opportunities A Acc SGD-H1","ATXI":"Avenue Therapeutics, Inc.","LU0882574055.USD":"富达全球健康医疗A ACC","LU1003076772.USD":"BGF EUROPEAN EQUITY INCOME \"A5G\" (USDHDG) INC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","NDAQ":"纳斯达克OMX交易所","LU0575583348.USD":"SCHRODER ISF UK EQUITY \"A\" (USD) INC AV","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0784384876.USD":"Blackrock Global Multi-Asset Income A6 USD","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0784385840.USD":"Blackrock Global Multi-Asset Income A2 USD","BK4007":"制药","LU1064927863.SGD":"JPMorgan Funds - Europe Dynamic A (acc) SGD-H","LU0345777659.USD":"NINETY ONE GSF EUROPEAN EQUITY \"A\" (USD) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","03165":"华夏欧优股对冲","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0964806797.USD":"UBS (LUX) EQUITY FUND - EUROPEAN OPPORTUNITY SUSTAINABLE (EUR) \"P\" (USHDG) ACC","LU0211326839.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) INC","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0784383803.USD":"BGF GLOBAL MULTI-ASSET INCOME FUND \"A\" (USD) INC A","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","AZN.UK":"阿斯利康制药","LU2114397693.USD":"BGF EUROPEAN EQUITY INCOME \"A\" (USDHDG) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4585":"ETF&股票定投概念","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0557290698.USD":"施罗德环球可持续增长基金","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1301847155.USD":"BGF GLOBAL MULTI-ASSET INCOME FUND \"A4G\" (USD) INC","LU1015430645.USD":"SCHRODER ISF UK EQUITY \"A\" (USDHDG) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","AXSM":"Axsome Therapeutics, Inc.","LU2279689827.SGD":"JPMorgan Investment Funds - Global Income Sustainable A (mth) SGD-H"},"translate_title":"Axsome Therapeutics获得AZD7325用于癫痫治疗的全球权利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"ATXI":0.9,"FBIO":0.9,"AXSM":0.9,"AZN.UK":0.9,"NDAQ":0.9},"content_text":"Axsome Therapeutics Acquires Global Rights to AZD7325 for Epilepsy Treatment\n    \n\n        Axsome Therapeutics has obtained exclusive global rights to AZD7325, a novel oral GABAA receptor α2,3 subtype-selective positive allosteric modulator, through the acquisition of 100% equity interest in Baergic Bio, Inc., a subsidiary of Avenue Therapeutics. The deal includes commercial, development, and manufacturing rights to AZD7325, which has shown anti-convulsant effects in preclinical seizure models and demonstrated a favorable safety and tolerability profile in clinical studies involving over 700 patients. Baergic Bio shareholders will receive a $0.3 million upfront payment, with potential development, regulatory, and sales-based milestone payments, as well as tiered royalties on global net sales. AstraZeneca, the original licensor, will receive a cash upfront payment in the single digit millions, additional milestone payments, and tiered royalties. Axsome plans to advance AZD7325 into Phase 2 trial-enabling activities for epilepsy in 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570134-en) on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}